Cancer

Pharmalot

Pharmalittle: Four drug companies settle Ohio opioid suit; J&J recalls baby powder due to asbestos

By Ed Silverman

Breast Cancer Cell - pink
Biotech

Seattle Genetics to seek approval for new breast cancer pill after positive clinical trial results

By Adam Feuerstein

23andme
Health

Competitor accuses 23andMe of ‘false negatives’ in cancer-gene testing

By Sharon Begley

Pharmalot

Pharmalittle: Five companies offer $50 billion deal to settle opioid suits; FDA approves record number of generics

By Ed Silverman

Sean Parker
Biotech

Sean Parker, billionaire and philanthropist, gets an immunotherapy company off the ground

By Adam Feuerstein

Live Chat

Archived chat: a discussion with 2019 Nobel laureate Dr. William Kaelin

By Sharon Begley

UT: Ancestry Headquarters
Health

Ancestry launches consumer genetics tests for health, intensifying rivalry with 23andMe

By Matthew Herper

Graphing Calculator
First Opinion

Accounting for hope: using ‘mean survival gain’ to price new cancer drugs

By Alice Chen and Dana Goldman

Male Breast Cancer
Health

Men account for a small fraction of breast cancer cases. Their fatality rate has soared compared with women’s

By Alexander Spinelli

Pharmalot

Pharmalittle: Puma takes two big price hikes; will we see a (generic) Vioxx redux?

By Elizabeth Cooney

Pharmalot

A small biotech raises the price on its cancer drug by 20% this year, but will anyone notice?

By Ed Silverman

Nobel Prize Medicine
In the Lab

Three scientists win Nobel Prize in medicine for discovering how cells sense and adapt to oxygen levels

By Sharon Begley

Dr Ben Davies
Biotech

‘It’s really a horrific situation’: What one doctor thinks about drug shortages‚ and how to solve them

By Adam Feuerstein, Damian Garde, and Rebecca Robbins

Pancreatic cancer organoid
In the Lab

Growing tumors in a dish, scientists try to personalize pancreatic cancer treatment

By Karen Weintraub

RNA illustration
Health

Beyond DNA testing: Can analyzing RNA turn up more patients at risk of cancer?

By Rebecca Robbins

Lung Cancer Cells
First Opinion

Blame rising cancer overdiagnosis on ‘irrational exuberance’ for early detection

By H. Gilbert Welch

FDA
Pharmalot

FDA challenges testing used by lab that found a carcinogen in Zantac and other heartburn meds

By Ed Silverman

Fortune telling
Don't Miss

What’s in the cards for this year’s Nobel Prizes? Scientists are placing their bets

By Sharon Begley

Microsoft logo with silhouette
Health Tech

Novartis partners with Microsoft to use AI in drug development

By Rebecca Robbins

Pharmalot

Pharmalittle: Step forward for ovarian cancer drugs; Pelosi’s drug pricing plan could hit hospitals hard

By Elizabeth Cooney

Play
Health

Watch: In a quest for more precise cancer care, hospitals invest in new tools — and new training, too

By Megan Thielking

Ovarian tissue
Pharma

AstraZeneca and GSK drugs reduce risk of ovarian cancer returning, studies find

By Matthew Herper and Damian Garde

human colon cancer cells
Biotech

Amgen’s KRAS-blocking drug shows minimal effect in colon cancer patients

By Adam Feuerstein

Documents
Pharmalot

Did someone say retraction? A dispute erupts over a paper about treating hyperthyroidism

By Ed Silverman

Biotech

Moderna will give Harvard researchers access to its RNA technology

By Kate Sheridan

Joerg Moeller
Pharma

First it was aspirin, then Xarelto. What’s Bayer’s next big thing?

By Eric Boodman

Malakkar Vohryzek
Health

‘I just want to live’: California man pleads with scientists around the world to ‘CRISPR me’

By Sharon Begley

Novartis Colombia
Pharmalot

Novartis expands recall of heartburn meds to U.S. after finding carcinogen

By Ed Silverman

Cokie Roberts
First Opinion

Cokie Roberts: A beacon for cancer survivors like me

By Steven Petrow

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy